zur Navigation zum Inhalt
 
Onkologie 2. April 2014

Case report of nab-paclitaxel in metastatic pancreatic cancer

The first biologically interactive albumin-bound paclitaxel in a nanometer particle is described in a patient with metastatic pancreatic cancer. The aim of this report is to underline the efficacy and tolerability of the new chemotherapy option. A 78-year-old male patient with metastatic pancreatic cancer received third-line nab-paclitaxel monotherapy in September 2011 until October 2012 in weekly or bi-weekly intervals. A partial response was detected by computed tomography scan 2 months after start of therapy, and this was confirmed after 5 and 8 months. While on therapy, 30 applications of nab-paclitaxel monotherapy allowed the patient to experience a solid partial response and a progression-free survival of 12 months. During treatment, the patient did not develop any side effects and experienced excellent quality of life. This experience emphasizes the potential clinical utility of nab-paclitaxel chemotherapy in the setting of metastatic pancreatic cancer.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben